Welcome to our dedicated page for Integrated Biopharma news (Ticker: INBP), a resource for investors and traders seeking the latest updates and insights on Integrated Biopharma stock.
Integrated BioPharma, Inc. reports operating results and business updates for an OTCQX-traded manufacturer and distributor of vitamins, nutritional supplements and herbal products. The company’s recurring news centers on quarterly and fiscal-year revenue, operating income or loss, net income per share and performance in its Contract Manufacturing Segment.
Company updates also discuss customer concentration among the segment’s largest customers, customer-base diversification, and activity tied to its core manufacturing, warehousing, distribution, marketing and sales operations.
Integrated BioPharma, Inc. (OTCQX:INBP) reported a revenue of $12.8 million for the quarter ended September 30, 2021, down 16% from $15.2 million in the same quarter of 2020. Operating income fell to $0.6 million from $1.5 million. Net income also decreased to $0.5 million or $0.02 per share, compared to $1.0 million or $0.04 per share last year. The drop in revenue was attributed to reduced demand post-COVID surge, although the company maintained a stable client base, with two major customers accounting for 91% of sales.
Integrated BioPharma (INBP) reported a strong performance for the quarter and fiscal year ending June 30, 2021. Revenues for Q4 reached $17.1 million, up 26.7% year-over-year, with net income of $4.5 million or $0.15 per share. For the fiscal year, total revenue was $63.6 million, a 20.5% increase, accompanied by net income of $8.0 million or $0.27 per share. Key customers in contract manufacturing accounted for 92% of revenues, demonstrating stable demand.
Integrated BioPharma (INBP) reported a 25.2% revenue increase for Q1 2021, totaling $17.1 million compared to Q1 2020. For the nine-month period, revenue reached $46.5 million, up 18.6% year-over-year. Operating income also rose from $1.0 million to $1.7 million for Q1, and net income increased from $0.9 million to $1.2 million during the same period. The company emphasized the consistency of revenue from its major customers, contributing 92% to total revenue.
Integrated BioPharma, Inc. (OTCQX: INBP) has launched an updated investors website aimed at enhancing shareholder engagement. Effective April 8, 2021, the site features current stock quotes, historical financial data, news, and events. Co-CEOs Riva Sheppard and Christina Kay emphasize that the reactivation of email subscription alerts will facilitate better communication with shareholders. The company focuses on manufacturing and distributing vitamins, nutritional supplements, and herbal products, ensuring transparency for investors.
Integrated BioPharma, Inc. (OTCQX:INBP) announced its financial results for Q2 2020, revealing revenue of $14.3 million, a slight increase from $14.2 million in Q2 2019. For the six-month period, revenue rose 14.8% to $29.4 million. The company reported net income of $1.2 million ($0.04 per share) for Q2 2020, up from $1.0 million ($0.03 per share) in 2019. Operating income remained stable at $1.2 million for both periods. The Co-CEOs highlighted consistency in revenue from their top two customers, making up 92% of total revenue.
Integrated BioPharma (OTCQB:INBP) announces a strong financial performance for Q3 2020, reporting revenue of $15.2 million, a significant increase of 33% from $11.4 million in Q3 2019. The company achieved an operating income of $1.5 million and a net income of $1.0 million ($0.04 per share), up from $0.3 million ($0.01 per share) the previous year. Notably, revenue from key customers remained stable, constituting 92% of total revenue. Eric Friedman joins the Board as a Class III director, contributing to future strategic developments.
Integrated BioPharma, Inc. (OTCQB:INBP) reported a 5.6% increase in revenues for the fiscal year ended June 30, 2020, reaching $52.8 million, compared to $50 million in 2019. Net income rose to $4.1 million or $0.14 per share, from $1.7 million or $0.06 per share the previous year. The operating income also increased to $3.3 million, reflecting a positive year amid COVID-19 challenges. Revenues from two major customers remained consistent, contributing approximately 92% of total revenue.